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(health plan name, income subsidy status). Descriptive analyses and chi-square 
tests were conducted to assess frequency distributions of the main adherence bar-
riers identified and their association with patients’ age, gender, income status, 
language and prescribers’ specialty. Results: Sample consisted of 87 hypertensive 
diabetic patients, non-adherent to ACE-Is/ARBs who received the pharmacist phone 
call. Among these patients, forgetfulness (25.29%) and doctor issue, like having diffi-
culty scheduling appointments, (16.79%) were the most commonly reported barriers. 
Other barriers identified included fear of adverse events (6.90%), cost and alterna-
tive source/insurance (5.75%), patient perception of disease and treatment (5.75%), 
dose reduction (5.75%), pharmacy related issue (3.45%), patient denial (2.30%), lost 
medication (1.15%), interruption (admission) (1.15%), transportation issues (1.15%), 
and no specified reason (2.30%). Chi-square test results were statistically insignifi-
cant (P> 0.05), thus indicating that these barriers didn’t vary across patients’ age, 
gender, language, income and prescribers’ specialty. ConClusions: Forgetfulness 
was the most commonly cited reason for non-adherence. Other barriers included 
doctor issue, fear of adverse events, cost, patient perception and dose reduction. 
Future interventions aimed at improving adherence among this high risk population 
should incorporate and address these identified barriers. KEYWORDS: Adherence, 
Intervention, ACEI/ARBs, Diabetes, Hypertension.
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objeCtives: Up to one third of older patients report cost-related medication 
non-adherence (CRMN). Diabetes is a costly chronic condition affecting 26 million 
Americans. There is an increasing recognition of the importance of CRMN in patients 
with diabetes. A behavioral framework for the factors influencing CRNM is needed 
to understand CRMN and design interventions. We aimed to develop a behavioral 
framework for CRMN among older diabetes patients. Methods: We conceptualized 
four dimensions of factors that may influence the CRMN in older diabetes patients: 
institutionalization, insurance coverage, diversity of drug utilization, and patient’s 
functional status. We used data from the 2010 Health and Retirement Study to 
assess those four dimensions. CRMN was self-reported. We conducted multivariate 
regression analysis to assess the effects of these potential risk factors. Results: 
875/4,880 (18%) of diabetes patients reported CRMN. In terms of institutionalization, 
patients residing in nursing home were 66% (p= 0.01) less likely to report CRMN; 
and having any number of hospitalizations increased the risk of CRMN (p< 0.01). 
In terms of insurance coverage, those at the pre-Medicare coverage aged 50-64 
years were 118% more likely to report CRMN compared to respondents who were 
age 65-74 (p< 0.01), and those with Medicaid were 66% less likely to report CRMN. 
In terms of drug utilization, patients using medication for asthma were 30% more 
likely to report CRMN (p< 0.01). In terms of functional status, patients with 1 or more 
limitations in activity of daily living or instrumental activities of daily living were 
much more likely to report CRMN (both p< 0.01). ConClusions: Patients’ CRMN is 
influenced by a range of factors. Interventions to reduce CRMN should target these 
factors and use these factors in identifying the target population for interventions.
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objeCtives: To evaluate the persistence rate and adherence level of new oral anti-
diabetics (OAD) users as well as their relation to patients’ demographic and clinical 
characteristics. Methods: A cohort of 160,231 patients was built from prescription 
records in the Régie de l’assurance maladie du Québec administrative database. All 
patients aged 45-85 years old who received at least one OAD prescription between 
January 2000 and October 2009 were included. New users were defined as having no 
OAD prescribed in the 2 years preceding cohort entry. The cohort entry was defined 
by the date of the first OAD prescription. Persistence rate was defined by allowing 
a 50% grace period for renewal. Drug adherence level was estimated using MPR. 
The cumulative persistence rate was estimated using a Kaplan-Meier analysis. Cox 
regression models were used to estimate the rate ratio of ceasing OAD after adjust-
ment. Logistic regression models were used to establish the relation between non-
adherence level and their determinants. Results: Patients had a mean age of 67 
years, 49% were men, 52% had a cardiovascular disease, 78% had hypertension and 
59% had dyslipidemia. Persistence decreased to 51% after 1 year but the proportion 
of patients who refilled an OAD during the year after cessation ranged from 73 to 
91%. Adherent patients (MPR ≥ 80%) accounted for 67% after 1 year. Hypertension 
(0.84-0.87), dyslipidemia (0.85-0.88) and cerebrovascular disease (0.89-0.99) were 
associated with higher persistence rates, whereas microvascular risk factors such 
as urologic procedure (1.01-1.17) and viral infectious diseases (1.09-1.27) demon-
strated lower rates. Similar results were observed for adherence. ConClusions: 
Barriers to persistence rate and adherence level occur early in the course of OAD 
therapy. Adherence is a key factor in determining the success of various therapeutic 
approaches, thus greater attention should be paid to this aspect which may result 
in improved patient outcome.
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objeCtives: To assess the impact of insulin pen needle (PN) length on persis-
tence of prescribed insulin therapy among patients recently diagnosed with type 2 
(P values <0.001) in the proportion of adherent patients (1 year  - saxagliptin: 49.1% 
vs. sitagliptin: 46.1%; 2 years – 41.5% vs. 39.3%) and the proportion of patients who 
discontinued (1 year – 43.4% vs. 46.4%; 2 years – 58.9% vs. 61.3%). Comparing saxa-
gliptin with sitagliptin, the adjusted odds ratio of being adherent during 1 year was 
1.21 (95% confidence interval: 1.16 –1.27) and during 2 years was 1.09 (1.01 –1.18). The 
adjusted hazard ratio of discontinuing saxagliptin during 1 year was 0.86 (0.84 –0.89) 
and during 2 years was 0.90 (0.86 –0.94) compared with sitagliptin. ConClusions: 
Among US adults with T2DM, saxagliptin was associated with greater adherence 
and persistence, compared with sitagliptin.  This research was funded by Bristol 
Myers Squibb and Astra Zeneca.
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objeCtives: To evaluate medication persistence with testosterone replacement 
therapy (TRT) in a US commercially-insured population. Methods: This was a 
retrospective claims database study using the MarketScan® Commercial database 
from January 2005 through December 2011. The study included men aged 18-65 
years who initiated TRT and were diagnosed with hypogonadism or hypogonado-
tropic hypogonadism (ICD-9-CM: 257.3 and 257.4). Subjects were required to have 
a minimum of 6 months continuous enrollment before and after the TRT index 
date. The main outcome was the percentage of patients who remained persistent 
with their index therapy, and estimated using the product-limit method. Results: 
Of 441,837 patients who had ≥ 1 TRT prescription claims during the study period, 
140,098 patients met all the inclusion and exclusion criteria. The mean age of the 
study population was 49.9 years (SD, 9.3 years). Most patients started with gels 
(54.1%), followed by short-acting injections (SAIs) (39%), patch (6%) and others (pel-
lets or buccal) (0.9%), respectively. Persistence with any TRT decreased substantially 
over the 36-month study period. About half of the patients were persistent with their 
TRT at 4 months while 36.9% and 24.4% of patients persisted at 6 and 12 months, 
respectively. The percentage of patients who stayed on therapy decreased to 13.6% 
(24 months) and 8.9% (36 months), respectively. For the analysis of persistence by 
formulation at 12 months, about a quarter of those receiving either gels or pellets 
remained on their initial therapy compared to 17.1% and 7.8% for SAIs and patch, 
respectively. ConClusions: This study showed that the persistence with testos-
terone replacement therapy among US patients decreased substantially over time. 
Treatment with long-acting formulations may help improving medication persis-
tence to derive long-term benefit from the therapy.
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objeCtives: The National Quality Forum is a public organization that reviews, 
endorses, and recommends use of standardized health care quality measures, 
which are considered the gold standard in the United States. The NQF endorses 
a measure concerning medication adherence in patients with diabetes using sul-
fonylureas, thiazolidinediones or metformin. This study tests the performance 
of the diabetes adherence quality measure in the Mississippi Medicaid popula-
tion. Methods: Mississippi Medicaid administrative claims for calendar years 2008 
to 2012 were used to assess the measure in the Mississippi Medicaid fee-for-service 
population. Eligible beneficiaries were at least 18 years of age, received at least 
two prescriptions in a specific therapeutic category and did not have any claims 
for insulin in the measurement period. The patient´s measurement period was 
defined as the period from the index prescription date to the end of the calendar 
year, disenrollment, or death. Adherence was defined as the number of covered 
days divided by total number of days in the measurement period. Results: The 
study population included had a higher proportion of females (approximately 75%), 
African-Americans (around 64%) and elderly (approximately 50%). Adherence to 
Sulfonylureas, Thiazolidinediones and Metformin was approximately 38%, 41% and 
39% respectively in 2008. These numbers decreased steadily to about 26%, 35% and 
26% respectively in 2012. ConClusions: Adherence to diabetes medications has 
been decreasing in the past few years. While this might reflect a need for greater 
adherence interventions, it is possible that these numbers are being caused by 
patients who are steadily moving from the fee-for-service plan to the managed 
care plan in Mississippi Medicaid. Nevertheless, adherence to diabetes medications 
is of critical importance to measuring quality of health care delivered. This study 
provides a valuable first look at the performance of this quality measure over several 
years in a Medicaid population.
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objeCtives: To identify main adherence barriers to ACE-Is/ARBs among non-adher-
ent hypertensive diabetic patients enrolled in a Texas-based Medicare Advantage 
plan through a pharmacist telephone intervention. Methods: Subjects were mem-
bers of a Medicare prescription drug plan in Texas. Medical claims data was used 
to identify patients who were diagnosed with hypertension and diabetes with at 
least 2 fills for ACE-Is or ARBs therapy January/2013- October/2013. Patients who 
failed to refill their medication for more than one day, and had a PDC< 0.8 were 
considered non-adherent and contacted by a pharmacist to identify the adher-
ence barrier(s). Pharmacy claims data included information on demographics (age, 
gender, language), prescriber/pharmacy information, and health plan information 
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objeCtives: Anti-diabetics have varying efficacy and safety profiles. This study 
aimed to better understand patient preferences for oral anti-diabetics by examining 
the relative importance (RI) of medication attributes that influence treatment selec-
tion among patients in the US with type 2 diabetes mellitus (T2DM). Methods: 
A web-based discrete choice experiment (DCE) was developed to assess the RI of 
7 medication attributes (effectiveness, hypoglycemia, weight change, gastrointes-
tinal/nausea side effects [SE], urinary tract infections [UTI]/genital infection SEs, 
blood pressure change, and cardiovascular risk). Participants were presented with 
2 hypothetical medications composed of varying levels of each attribute and asked 
to select the preferred profile. Part-worth utility values, or preference weights, were 
calculated to provide information on the extent to which participants preferred 
one level of an attribute over another and used to derive RI values. RI values were 
calculated based upon the relative weight of each attribute in the sum of part-worth 
utility values, with higher values indicating greater importance. Results: A total 
of 809 invitations were sent; 54% responded. The final sample was composed of 
the first 200 eligible participants with self-reported T2DM (50% male, mean age 
60.9 years). The RI values for the attributes in order of importance were effective-
ness (25.9%), hypoglycemic events (21.5%), weight change (21.0%), gastrointestinal/
nausea SEs (14.1%), UTI/genital infection SEs (11.0%), blood pressure (3.7%), and 
cardiovascular risk (2.9%). Effectiveness, hypoglycemic events, and weight change 
comprised 68.4% of the RI. ConClusions: Results suggest that effectiveness, hypo-
glycemic events, and weight change are the predominant influences on patients’ 
medication decisions for T2DM. These results were consistent with findings from 
a DCE conducted in the United Kingdom (UK), which utilized a similar methodol-
ogy and yielded similar RI results. The confluence of these findings highlights the 
importance of these attributes as drivers of medication decisions in patients with 
T2DM in the United States and UK.
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objeCtives: To elicit preferences of injection-naïve patients with type 2 diabetes 
mellitus (T2DM) for features of glucagon-like peptide-1 receptor agonist (GLP-1RA) 
injections using a discrete-choice experiment; to test for effect of injection fre-
quency on patient preferences. Methods: Injection-naïve adults in the United 
States with self-reported physician diagnosis of T2DM completed a web-enabled, 
discrete-choice experiment (DCE). The survey presented patients with a series 
of 10 choice questions, each including a pair of hypothetical GLP-1RA injection 
profiles with equivalent efficacy and side effects. Each profile was defined by the 
following pre-determined attributes identified from patient interviews: frequency 
of injections (weekly, daily), injection device (multiple-use injection pen, single-
use injection pen, single-use vial and syringe), needle size (shorter and thinner, 
longer and thicker), need for refrigeration, and injection-site nodules. Choice ques-
tions were based on a pre-determined experimental design with known statisti-
cal properties allowing for interaction effects between injection frequency and 
other injection features. Random-parameters logit was used to estimate pref-
erences. Results: A total of 184 respondents completed the survey; 50% were 
women and mean age (SD) was 60.8 (11.0) years. Injection frequency was the most 
important attribute compared with all other attributes in the DCE. Preferences 
for all injection features were dependent on frequency of injections; that is, the 
estimated preference parameter on the interaction between injection frequency 
and each treatment feature was statistically significant. Negative injection fea-
tures were statistically significantly less important to patients if injections were 
weekly instead of daily. For all possible injection profiles included in the design, a 
greater proportion of patients preferred a weekly injection compared with a daily 
injection. ConClusions: In this study, several device attributes were suggested 
to predict treatment choice in injection-naïve T2DM patients. Results suggest that 
injection frequency is of primary importance and key to understanding patient 
preferences for injectable diabetes treatments.
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objeCtives: The objective of this study was to estimate the effect of both diabetes 
related symptoms, outcomes and concomitant conditions on the HRQoL as reported 
by diabetes patients. Methods: A cross-sectional survey of diabetes patients (n 
= 1480) living in the United States. Each patient completed a questionnaire, which 
included the EQ-5D-5L instrument and accompanying VAS. Patients were also asked 
to state which diabetes symptoms and concomitant conditions they are suffering 
from. By means of logistic linear modeling the health utility scores derived from 
the EQ-5D-5L were linked to symptoms and concomitant conditions. Results: All 
tested diabetes symptoms and concomitant conditions together explain up to 52% 
of the variation in health utility scores (R² = 0,52). Out of 35 tested symptoms and 
concomitant conditions, 8 had a significant negative impact on HRQoL ( p-value < 
0,001). Ranked in order of standardized β -value these are: depression (β -value: -0,25), 
arthritis (β -value: -0,21), neuropathy (β -value: -0,16), (mini)-stroke (β -value: -0,11), 
blood circulation problems (β -value: -0,09), pain in hands or feet (β -value: -0,09), 
foot sores and ulcers (β -value: -0,08), and high blood pressure (β -value: -0,07). For 
all other symptoms or concomitant conditions lower levels of significance were 
found. ConClusions: Diabetes related symptoms and concomitant conditions are 
a significant driver of reduced levels of HRQoL. Depression and arthritis are the two 
concomitant conditions with the highest negative impact on HRQoL.
diabetes mellitus (T2DM). Methods: Patients 18 years and older diagnosed with 
T2DM who had at least one indexed claim from May 2009 through September 2010 
were assessed from the Truven Health MarketScan Research Database. Inclusion 
required 1 year continuous enrollment pre and post-index insulin claim with ≤ 
1 prescription for an oral anti-diabetic drug during the pre-index period. Patients 
diagnosed with T1DM or using specialty self-injectables during the pre-index period 
were excluded. Patients were grouped into three PN length cohorts: short (4 & 5mm), 
intermediate (6mm) and long (8 & 12.7mm) needle initiators. Persistence was evalu-
ated at 6 and 12 months by the absence of 90 day gaps between insulin prescriptions. 
Differences in persistence between cohorts were compared for statistical signifi-
cance using a Fisher’s exact test (95% CI, two-tail). Results: The study included 21,622 
patients with an average age of 59.1 years (SD= 11.4). Most patients were within the 
long needle group (67.6%); followed by the short (21.5%) and intermediate (10.8%) 
needle users. The majority of patients were non-persistent at the end of the first 
year of insulin use, with only 38.4% being persistent. Within the first 6 months only 
46.5% of patients were found to be persistent. However, of those patients who were 
persistent within first 6 months, the likelihood of them remaining persistent was 
high with 82.6% of users reporting no gaps at 1 year. When examining the correlation 
between needle length and persistence, short needle users were 4.9% (p< 0.001) and 
2.7% (p= 0.001) more persistent at 6 months than intermediate and long needle users, 
respectively. ConClusions: Persistence rates were higher for those patients using 
shorter needles, particularly early on at earlier phases of insulin adoption.
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objeCtives: Although health status among patients with type 2 diabetes (T2D) in 
Japan can be improved with advances in treatment, there are other modifiable fac-
tors which could also be examined as potential targets for intervention. This study 
examined the association of adherence and health behaviors with health status in 
this population. Methods: Data from the Japan 2012 National Health and Wellness 
Survey (NHWS) were used (N= 30,000). Only respondents who reported a diagnosis of 
T2D and who were currently using a prescription medication were included (n= 892). 
Smoking, exercise behavior, obesity, alcohol use, and medication adherence (meas-
ured using the MMAS-8) were used as predictors of health status (measured using 
the SF-36v2) controlling for demographics and comorbidities. Results: 79.7% of 
respondents were male; the mean age was 62.2 years. Nearly two-thirds of patients 
had a history of smoking (23.4% were current smokers and 41.9% were former smok-
ers) and over a quarter consumed alcohol daily. Patients exercised a mean of 8 days 
per month and over 40% of patients were either overweight (29.4%) or obese (11.4%). 
Forgetfulness was the most common reason for non-adherence with medication 
(forgetting, 49.4%; difficulty remembering, 32.8%; forgetting when traveling/leav-
ing home, 30.8%). Controlling for demographics and comorbidities, the strongest 
predictors of health status were with smoking (b = -1.62 for PCS), obesity (b = -3.16 
for PCS), exercise (b = 0.15 for PCS), and not taking medications the prior day (b = 
-1.85 for PCS) (all p< .05). ConClusions: Smoking cessation, improved exercise and 
weight reduction may result in significant health status improvements, aside from 
their well-known clinical benefits. Although forgetting medication was common 
among patients with T2D, the very act of taking or not taking medication the day 
before was predictive of physical health status. Interventions which can improve 
adherence rates could also have significant health status benefits.
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objeCtives: Weight satisfaction (WS) has been shown to be associated with posi-
tive health behaviors important for optimal management of type 2 diabetes mel-
litus (T2DM). In a previously reported study of CANA vs. PBO in triple therapy with 
metformin and sulfonylurea in addition to background diet and exercise, CANA was 
associated with significant reduction in body weight vs. PBO at 26 weeks, with an 
absolute mean weight loss of up to -2.52 kg (SE = 0.29). The objective of this analy-
sis was to explore the direction and strength of the relationship between weight 
change and change in WS using data from this trial. Methods: The Current Health 
Satisfaction Questionnaire was administered at baseline and over time to capture 
agreement with a statement about WS. Subjects were re-classified into 2 catego-
ries at baseline, satisfied or dissatisfied/neutral, based upon responses to a 7-point 
Likert-style scale. Differences in least square (LS) mean change in weight by changes 
in WS after 26 weeks were compared regardless of treatment using ANCOVA models 
and adjusted for selected baseline covariates (i.e., weight, age, and gender). Logistic 
regression, adjusted for the same covariates, was used to generate odds ratios (OR) 
for changes in WS associated with weight change. Results: Of the subjects in the 
study (n = 386), 75.6% were dissatisfied/neutral with their body weight at baseline. 
Subjects with improved WS lost more weight on average than those with no WS 
improvement (difference in LS means = -1.52 kg [95% CI: -2.68, -0.36]). Weight loss 
of 3kg was associated with a 54% greater chance of an improvement in WS from 
dissatisfied/neutral to satisfied (OR = 1.54; 95% CI: 1.15, 2.05). ConClusions: These 
results suggest that an amount of weight loss in the range achieved by subjects tak-
ing CANA is noticeable and important to people living with T2DM.
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